Details

Autor(en) / Beteiligte

• Riedel, Sebastian L.
• Jahns, Stefan
• Koenig, Steven
• Bock, Martina C.E.
• Brigham, Christopher J.
• Bader, Johannes
• Stahl, Ulf

Titel

Polyhydroxyalkanoates production with Ralstonia eutropha from low quality waste animal fats

Ist Teil von

• Journal of biotechnology, 2015-11, Vol.214, p.119-127

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •Industrial rendered animal waste streams were used to produce PHA with Ralstonia eutropha.•Fats with high melting temperatures and free fatty acid contents were used.•No chemical or mechanical treatment was used for emulsification of the fats.•PHA production in 5-L fermenter: 45g/L CDW, 60% P(HB-co-19mol%HHx) per CDW. Polyhydroxyalkanoates (PHAs) are biodegradable and biocompatible polyesters considered as alternatives to petroleum-based plastics. Ralstonia eutropha is a model organism for PHA production. Utilizing industrially rendered waste animal fats as inexpensive carbon feedstocks for PHA production is demonstrated here. An emulsification strategy, without any mechanical or chemical pre-treatment, was developed to increase the bioavailability of solid, poorly-consumable fats. Wild type R. eutropha strain H16 produced 79–82% (w/w) polyhydroxybutyrate (PHB) per cell dry weight (CDW) when cultivated on various fats. A productivity of 0.3g PHB/(L×h) with a total PHB production of 24g/L was achieved using tallow as carbon source. Using a recombinant strain of R. eutropha that produces poly(hydroxybutyrate-co-hydroxyhexanoate) [P(HB-co-HHx)], 49–72% (w/w) of PHA per CDW with a HHx content of 16–27mol% were produced in shaking flask experiments. The recombinant strain was grown on waste animal fat of the lowest quality available at lab fermenter scale, resulting in 45g/L CDW with 60% (w/w) PHA per CDW and a productivity of 0.4g PHA/(L×h). The final HHx content of the polymer was 19mol%. The use of low quality waste animal fats as an inexpensive carbon feedstock exhibits a high potential to accelerate the commercialization of PHAs.